Schmuck, et al. (6060. Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2017; 44:960-8.) |
R |
Germany |
240 |
180 |
PSA, Histology and follow-up |
59.8±7.5 |
Patients with recurrent prostate cancer |
68Ga-PSMA PET had high detection rates in patients with persistent PSA or biochemical persistence of prostate cancer. |
Uprimny, et al. (6161. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, et al. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017; 44:765-75.) |
R |
Austria |
80 |
60 |
PSA |
47-92 |
Patients with recurrent prostate cancer |
68Ga-PSMA PET is reliable in distinguishing lesion from bladder activity |
Berliner, et al. (6262. Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, et al. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. Eur J Nucl Med Mol Imaging. 2017; 44:670-7.) |
R |
Germany |
83 |
80 |
PSA |
68±7 |
Patients with biochemical recurrence of prostate cancer |
68Ga-PSMA PET has high rates of detection of recurrent cancer, the higher the level of PSA the greater the detection rate |
Einspieler, et al. (6363. Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, et al. Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. J Nucl Med. 2017; 58:1081-7.) |
R |
Germany |
118 |
60 |
Histology |
50-87 |
Patients with biochemical recurrence of prostate cancer |
68Ga-PSMA PET has high levels of cancer detection |
Kabasakal, et al. (6464. Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, et al. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nucl Med Commun. 2017; 38:149-55.) |
R |
Turkey |
50 |
60 |
Change in PSA levels posterior 171Lu-PSMA treatment |
67.3±8.7 |
Patients referred for restaging |
68Ga-PSMA PET is accurate to reestablish patients with relapse |
Schwenck, et al. (6565. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017; 44:92-101.) |
R |
Germany |
123 |
60 |
PSA |
– |
Patients with recurrent prostate cancer |
PSMA is more accurate than C-choline to detect lymph nodes and bone lesions |
Hruby, et al. (6666. Hruby G, Eade T, Kneebone A, Emmett L, Guo L, Ho B,et al. Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Radiother Oncol. 2017; 122:99-102.) |
C |
Australia |
419 |
|
Biochemical recurrence |
– |
Patients submitted to radiotherapy |
68Ga-PSMA PET detected all cases of biochemical recurrence |
Dietlein, et al. (8787. Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015; 17:575-84.) |
P |
Germany |
129 |
60-120 |
PSA |
– |
Patients with biochemical recurrence of prostate cancer |
F-DCFPyL is not inferior than 68Ga-PSMA-HBED-CC |
Meredith, et al. (6868. Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, et al. The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016; 118 Suppl 3:49-55.) |
R |
Australia |
532 |
60 |
PSA |
44-85 |
Patients with biochemical recurrence of prostate cancer |
68Ga-PSMA PET s a new imaging modality to detect prostate cancer |
Bluemel, et al. (5959. Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, et al. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med. 2016; 41:515-21.) |
R |
Germany |
32 |
60 |
PSA |
69.4±6.8 |
Patients with biochemical recurrence of prostate cancer and negative Choline-PET/CT |
Including 68Ga-PSMA PET in Choline-PET / CT negative patients increases the ratio of positive diagnoses |
Pfister, et al. (6969. Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F, et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:1410-7.) |
P |
Germany |
28 |
45 |
Histopathology |
46-79 |
Patients with biochemical recurrence of prostate cancer |
68Ga-PSMA PET is more accurate than Fluoroethylcholine PET/CT |
Sachpekidis, et al. (7070. Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, et al. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging. 2016; 43:1288-99.) |
– |
Germany |
31 |
60 |
PSA |
54-77 |
Patients with biochemical recurrence of prostate cancer |
68Ga-PSMA PET has promising and satisfactory detection levels |
Henkenberen, et al. (7171. Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, et al. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy. Strahlenther Onkol. 2016; 192:431-9.) |
P |
Germany |
29 |
|
PSA |
51-86 |
Patients with biochemical recurrence of prostate cancer |
Radiation therapy guided by 68Ga-PSMA PET has good results |
van Leeuwen, et al. (7272. van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016; 117:732-9.) |
P |
Australia |
70 |
45 |
PSA |
57-67 |
Patients with biochemical recurrence of prostate cancer |
68Ga-PSMA PET has reasonable performance in identifying recurrence of prostate cancer in patients with low PSA |
Verburg, et al. (7373. Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016; 43:397-403.) |
R |
Germany |
155 |
60 |
PSA |
43-86 |
Patients with biochemical recurrence of prostate cancer |
68Ga-PSMA PET is a promising and clinically useful tool |
Ceci, et al. (7474. Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015; 42:1284-94.) |
R |
Austria |
70 |
60 |
PSA |
38-91 |
Patients with biochemical recurrence of prostate cancer |
68Ga-PSMA PET has the potential confirmed in patients with biochemical relapse |
Eiber, et al. (7575. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56:668-74.) |
R |
Germany |
248 |
54 |
PSA |
46-85 |
Patients with recurrent prostate cancer |
68Ga-PSMA PET has a substantially higher detection rate compared to other imaging tests |
Afshar-Oromieh, et al. (7878. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42:197-209.) |
R |
Germany |
310 |
60 |
PSA and Histology |
46-86 |
Patients with recurrent prostate cancer |
68Ga-PSMA PET can detect the recurrence of prostate cancer in a large number of patients |
Afshar-Oromieh, et al. (66. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41:11-20.) |
R |
Germany |
37 |
60 |
PSA and Histology |
57-85 |
Patients with recurrent prostate cancer |
68Ga-PSMA PET identifies a larger number of patients than Fluoroethylcholine |
Afaq, et al. (7777. Afaq A, Alahmed S, Chen SH, Lengana T, Haroon A, Payne H, et al. Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. J Nucl Med. 2018; 59:89-92.) |
R |
UK |
100 |
60 |
Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time |
79-89 |
patients with BCR |
68Ga-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive 68Ga-PSMA scan results, and higher PSA levels. |
Akdemir, et al. (7979. Akdemir EN, Tuncel M, Akyol F, Bilen CY, Baydar DE, Karabulut E, et al. 68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer. World J Urol. 2019; 37:813-21.) |
P |
Turkey |
121 |
60 |
Conventional imaging |
51-92 |
Patients with recurrent prostate cancer |
68Ga-PSMA-PET/CT is useful for re-staging patients with RPCa and has improved performance compared with CI for disease detection. |
Barbaud, et al. (8080. Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, et al. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes. Prostate. 2019; 79:454-61.) |
R |
France |
42 |
60 |
FCH PET-CT |
57-80 |
Prostate Cancer patients with previously negative or doubtful 18F-Choline (FCH) |
Performing a PSMA PET-CT when FCH PET-CT was doubtful or negative allows the recurrence localization in more 80% of patients and this had a major clinical impact, as it resulted in treatment change in more than 70% of patients as well as a significant decrease in PSA levels in more than 60% of them. |
Bashir, et al. (8181. Bashir U, Tree A, Mayer E, Levine D, Parker C, Dearnaley D, et al. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019; 46:901-7.) |
R |
UK |
28 |
60 |
Follow up |
50-76 |
patients with early BCR post RP |
Our findings show that PSMA-PET/CT has a high detection rate in the eBCR setting following RP, with a large proportion of patients found to have fewer than three lesions. |
Calais, et al. (8282. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, et al. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018; 59:434-41.) |
P |
USA |
101 |
52-96 |
Referring physicians questionnaires |
– |
patients with proven prostate adenocarcinoma and BCR after prostatectomy or definitive radiotherapy. |
This prospective referring physician–based survey shows a significant impact (54/101; 53%) of 68Ga-PSMA-11 PET/CT on the actual management of prostate cancer patients with BCR. Importantly, intended management changes after 68Ga-PSMA-11 PET/CT were further modified in almost 50% of the patients, underlining the limitations of survey-based management assessment |
Calais, et al. (8383. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018; 59:230-7.) |
R |
USA |
270 |
59 |
Referring physicians questionnaires |
43-90 |
patients with prostate cancer BCR |
Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes. |
Caroli, et al. (8484. Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, et al. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. 2018; 45:2035-44.) |
P |
Italy |
314 |
50 |
PSA level |
44-92 |
Patients with BCR of PCa after radical surgery and/or radiotherapy with or without androgen-deprivation therapy |
We confirmed the value of 68Ga-PSMA PET/CT in restaging PCa patients with BCR, highlighting its superior performance and safety compared with choline PET/CT. Higher PSApet was associated with a higher relapse detection rate. |
Ceci, et al. (8585. Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, et al. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2019; 46:31-9.) |
P |
Italy |
332 |
60 |
PSA level |
54-83 |
Men with proven PCa, submitted surgery or radiotherapy as definitive therapy, with proven BCR, prostate-specific antigen (PSA) 0.2-2 ng/mL, ≥ 35 years |
Our data confirmed the efficacy of 68Ga-PSMA-11 PET/CT for detecting local vs systemic disease in PCa patients presenting PSA failure after radical therapy. Furthermore, 68Ga-PSMA-11 PET/CT detection rate is different depending on the clinical stage of BCR, and this information should be taken into consideration by referring physicians. |
Dewes, et al. (8686. Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol. 2016;11:73.) |
R |
Germany |
15 |
NA |
PSA levels |
59-82 |
patients treated for PC between August 2013 and April 2015 that were ere planned for definitive RT of the prostate with treatment planning based on CT, MRI and 68Ga-PSMA-PET-imaging. |
The integration of (68)Ga-PSMA-PET-imaging into the RT treatment planning process can be useful for detailed target volume planning. The performance of a (68)Ga-PSMA-PET frequently leads to changes in the TNM stage, altering the RT treatment regimen and the target volume. A prospective trial is underway to evaluate the impact of (68)Ga-PSMA-PET based treatment planning on outcome. |
Dietlein, et al. (6767. Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2017; 58:947-52.) |
P |
Germany |
129 |
60-120 |
18F-DCFPyL |
– |
patients with biochemical recurrence of prostate cancer |
Our data suggest that 18F-DCFPyL is noninferior to 68Ga-PSMA-HBED-CC, while offering the advantages of 18F labeling. Our results indicate that imaging with 18F-DCFPyL may even exhibit improved sensitivity in localizing relapsed tumors after prostatectomy for moderately increased PSA levels. Although the standard acquisition protocols, used for 18F-DCFPyL and 68Ga-PSMA-HBED-CC in this study, stipulate different activity doses and tracer uptake times after injection, our findings provide a promising rationale for validation of 18F-DCFPyL in future prospective trials. |
Fendler, et al. (8888. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019; 5:856-63.) |
P |
USA |
635 |
64+ |
Histopathologic analysis |
44-95 |
patients with biochemically recurrent prostate cancer after prostatectomy |
Using blinded reads and independent lesion validation, we establish high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer. |
Fennessy, et al. (8989. Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, et al. Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer. J Med Imaging Radiat Oncol. 2017; 61:739-44.) |
P |
Australia |
62 |
60 |
PSA Level |
47-89 |
men with prostate cancer undergoing clinically indicated 68 Ga-PSMA PET/CT |
Intravenous Frusemide given with 68 Ga-PSMA reduces excretion artefact, and improves diagnostic certainty. Frusemide should be considered for all 68 Ga-PSMA PET/CT imaging protocols. |
Gauthé, et al. (9090. Gauthé, M et al. “TEP/TDM et récidive biologique d'adénocarcinome prostatique: apport du 68Ga-PSMA-11 lorsque la 18F-fluorocholine n'est pas contributive” [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive]. Progrès en Urologie 2017;27: 474-81. Available at. < https://www.urofrance.org/sites/default/files/fileadmin/documents/data/PU/2017/3247/69449/FR/1128952/main.pdf> https://www.urofrance.org/sites/default/...
) |
P |
France |
33 |
60 |
PSA level |
55-79 |
patients presenting biochemical recurrence of prostate cancer whose 18Ffluorocholine (FCH) PET/CT was non-contributive |
68Ga-PSMA-11 PET/CT is useful in detecting recurrence of prostate cancer, by identifying residual disease which was not detected on other imaging modalities and by changing management of 2 patients out of 3. |
Hamed, et al. (9191. Hamed MAG, Basha MAA, Ahmed H, Obaya AA, Afifi AHM, Abdelbary EH. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy. Acad Radiol. 2019; 26:450-60.) |
P |
Egypt |
188 |
60 |
Histopathology, clinical and imaging follow up |
56-79 |
patients who exhibited rising of PSA level on a routine follow-up examination after definitive treatment of PC |
68Ga-PSMA PET/CT is a valuable tool for the detection of PC local recurrence or extraprostatic metastases following risin |
Hijazi, et al. (2424. Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015; 75:1934-40.) |
R |
Germany |
35 |
60-180 |
PSA and biopsy |
49-77 |
Confirmed Prostate Cancer or Patients with biochemical relapse |
68Ga-PSMA PET improves the accuracy of micro-metastases diagnosis |
Hope, et al. (9292. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017; 58:1956-61.) |
P |
USA |
150 |
63±10 |
Referring physicians questionnaires |
69±6.9 |
a prostate-specific antigen (PSA) doubling time of less than 12 mo after initial treatment |
68Ga-PSMA-11 PET resulted in a major change in management in 53% of patients with biochemical recurrence. Further studies are warranted to investigate whether PSMA-based management strategies result in improved outcomes for patients. |
Jilg, et al. (9393. Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, et al. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. Theranostics. 2017; 7:1770-80.) |
R |
Germany |
30 |
50 |
Imunohistochemistry |
– |
patients with the suspicion of exclusively nodal PCa-relapse after primary therapy underwent a template pelvic and/or retroperitoneal salvage-LND after whole body 68-Ga-PSMA-PET/CT |
In men with biochemical PCa-relapse and positive PSMA-PET/CT, PET/CT detects metastatic affected anatomical regions with high accuracy at a main region and at a subregion-level. If the decision for salvage-LND is prompted by a positive PSMA-PET/CT, the size of metastases is crucial for accurate detection of affected regions. |
Mattiolli, et al. (9494. Mattiolli AB, Santos A, Vicente A, Queiroz M, Bastos D, Herchenhorn D, et al. Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study. Int Braz J Urol. 2018; 44:892-9.) |
R |
Brazil |
126 |
60 |
PSA levels |
43-89 |
prostate cancer patients submitted to the 68Ga-PSMA PET / CT due to biochemical recurrence |
68Ga-PSMA PET / CT in prostate cancer patients with biochemical recurrence has a high impact in patient management. |
McCarthy, et al. (9595. McCarthy M, Francis R, Tang C, Watts J, Campbell A. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging. Int J Radiat Oncol Biol Phys. 2019; 104:801-8.) |
P |
Australia |
238 |
60 |
PSA levels |
46-91 |
All patients had histologically confirmed PCa with biochemical relapse after definitive prostatectomy or radiation therapy. Patients with biochemical relapse at least 6 months after previous response to systemic (hormonal) treatment were also included. |
PSMA PET/CT is significantly more sensitive than standard restaging imaging, and it may be useful in identifying patients for subsequent targeted therapy. |
Morigi, et al. (9696. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015; 56:1185-90.) |
P |
Australia |
38 |
45 |
8F-fluoromethylcholine |
54-81 |
A sample of men with a rising PSA level after treatment, eligible for targeted treatment, was prospectively included |
In patients with biochemical failure and a low PSA level, (68)Ga-PSMA demonstrated a significantly higher detection rate than (18)F-fluoromethylcholine and a high overall impact on management. |
Pfister, et al. (6969. Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F, et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:1410-7.) |
P |
Germany |
28 |
45 |
Lymphadenectomy |
46-79 |
Prostate Cancer patients who underwent sLAD after PET/CT |
In the present series Ga-PSMA PET/CT shows a better performance than FEC PET/CT with a significantly higher NPV and accuracy for the detection of locoregional recurrent and/or metastatic lesions prior to salvage lymphadenectomy. |
Rauscher, et al. (9797. Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. J Nucl Med. 2016; 57:1713-9.) |
R |
Germany |
48 |
49-63 |
Salvage lymphadenectomy |
66-74 |
patients with biochemical recurrence who underwent 68Ga-prostate-specific membrane antigen (PSMA) HBED-CC PET/CT or PET/MR and salvage lymphadenectomy |
68Ga-PSMA HBED-CC PET imaging is a promising method for early detection of LNM in patients with biochemical recurrent prostate cancer. It is more accurate than morphologic imaging and thus might represent a valuable tool for guiding salvage lymphadenectomy. |
Schmidkonz, et al. (9898. Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, et al. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer. Clin Nucl Med. 2018; 43:225-31.) |
R |
Germany |
93 |
180-240 |
Follow up |
51-81 |
subjects conforming to the following criteria: histopathologically confirmed PC by needle biopsy and no primary therapy |
MIP-1404 SPECT/CT has a high accuracy and low interobserver variability in the diagnosis of PC and allows detection of lymph node and bone metastases in a significant proportion of as yet untreated PC patients. |
Schmidt-Hegemann, et al. (7676. Schmidt-Hegemann NS, Eze C, Li M, Rogowski P, Schaefer C, Stief C, et al. Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. J Nucl Med. 2019; 60:963-70.) |
R |
Germany |
172 |
60 |
Conventional CT |
46-86 |
Prostate Cancer patients underwent 68Ga-PSMA PET/CT before radiotherapy |
Compared with conventional CT, 68Ga-PSMA PET/CT had a remarkable impact on radiotherapeutic approach, especially in postoperative patients. |
Walacides, et al. (9999. Walacides D, Meier A, Knöchelmann AC, Meinecke D, Derlin T, Bengel FM, et al. Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. Strahlenther Onkol. 2019; 195:420-9.) |
R |
Germany |
25 |
? |
Conventional Imaging |
50-85 |
patients with biochemical prostate cancer recurrence after primary prostatectomy underwent 68 Ga-PSMA ligand PET/CT in addition to conventional imaging techniques such as CT and/or MR imaging for restaging |
68 Ga-PSMA ligand PET/CT is superior to conventional cross-sectional imaging for the delineation of lymph node metastases from prostate cancer. |
Wondergem, et al. (100100. Wondergem M, van der Zant FM, Knol RJJ, Lazarenko SV, Pruim J, de Jong IJ. 18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. J Nucl Med. 2017; 58:1797-804.) |
P |
Netherlands |
65 |
60 or 120 |
PSA level |
52-84 |
prostate cancer patients who were referred to our nuclear medicine department for 18F-DCFPyL PET/CT were included |
18F-DCFPyL PET/CT images at 120 min after injection yield a higher detection rate of prostate cancer characteristic lesions than images at 60 min after injection. Further studies are needed to elucidate the best imaging time point for 18F-DCFPyL. |
Zacho, et al. (101101. Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, et al. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018; 45:1884-97.) |
P |
? |
68 |
60 |
18F-NaF PET/CT |
47-80 |
PCa patients with BCR |
68Ga-PSMA PET/CT and 18F-NaF PET/CT showed comparable and high diagnostic accuracies for detecting bone metastases in PCa patients with BCR. |